Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624770 | 1.00 | HDAC2 (0.45) | HDAC2HDAC3KCNH2HDAC1ALDH1A1 | |
| SCHEMBL1625106 | 0.92 | HDAC1 (0.46) | HDAC2HDAC3KCNH2HDAC1ALDH1A1 | |
| SCHEMBL1624353 | 0.82 | TRPV1 (0.51) | HDAC2HDAC3KCNH2TRPV1MCHR1 | |
| SCHEMBL1625531 | 0.82 | TRPV1 (0.51) | HDAC2HDAC3KCNH2TRPV1MCHR1 | |
| SCHEMBL1625471 | 0.79 | ITK (0.48) | HDAC2HDAC3HDAC1 | |
| SCHEMBL13894037 | 0.76 | ITK (0.50) | HDAC2HDAC3KCNH2HDAC1 | |
| SCHEMBL171721 | 0.75 | ITK (0.51) | HDAC2HDAC3KCNH2HDAC1 | |
| SCHEMBL1625212 | 0.74 | NPC1 (0.60) | — | |
| SCHEMBL6925885 | 0.74 | CNR2 (0.56) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6925668 | 0.73 | CNR2 (0.53) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | claimed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | claimed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | claimed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | GLI1, SHH, SMO | HDAC2 1103/4885HDAC3 346/4885KCNH2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.